Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment of Bleeding Clear all
Terminated Phase 1Phase 2 Interventional

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

NCT00547066
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune
Interventions
veltuzumab
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Riverdale, Georgia • Tucker, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Minitouch Endometrial Ablation System Treatment for Menorrhagia: An Evaluation of Safety & Effectiveness

NCT04267562
View directory record Official record
Conditions
Menorrhagia, Heavy Menstrual Bleeding, Heavy Uterine Bleeding
Interventions
Minitouch System
Device
Lead sponsor
MicroCube, LLC
Industry
Eligibility
30 Years to 50 Years · Female only
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
5
States / cities
Newburgh, Indiana • Mason, Ohio • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

NCT02267226
View directory record Official record
Conditions
Congenital Fibrinogen Deficiency
Interventions
Octafibrin
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 25, 2026, 4:56 PM EDT
Active, not recruiting Not applicable Interventional

Amplatzer Amulet LAAO vs. NOAC

NCT04226547
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
No Longer Available No phase listed Expanded access

Aprotinin US Special Access Protocol

NCT00611845
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Aprotinin (Trasylol, BAYA0128)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Decatur, Alabama • Glendale, California • Pismo Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2014 · Synced Sep 25, 2026, 4:56 PM EDT
Not listed Not applicable Interventional

Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding

NCT01659008
View directory record Official record
Conditions
Menstrual Cycle and Uterine Bleeding Disorders
Interventions
Estradiol, Lysteda
Drug
Lead sponsor
Kay I Waud MD PhD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Early Phase 1 Interventional

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

NCT00486421
View directory record Official record
Conditions
Nonneoplastic Condition
Interventions
Rituximab, Prednisone
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 25, 2026, 4:56 PM EDT
Not listed Phase 2 Interventional

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

NCT00107913
View directory record Official record
Conditions
Autoimmune Thrombocytopenic Purpura
Interventions
Doxil
Drug
Lead sponsor
Hematology and Oncology Specialists
Other
Eligibility
0 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 4:56 PM EDT
Completed No phase listed Observational Results available

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

NCT02022020
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Aurora, Colorado • New Britain, Connecticut • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of a Facemask Device to Treat Hypotension

NCT00256724
View directory record Official record
Conditions
Hypotension
Interventions
Impedance Threshold Device, sham ITD
Device
Lead sponsor
Advanced Circulatory Systems
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 25, 2026, 4:56 PM EDT
Terminated Phase 4 Interventional Results available

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

NCT00559988
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions
Home Monitoring Guided OAC, Physician-Directed OAC
Drug
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

NCT05714969
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Gainesville, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A

NCT03528551
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
Turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Phoenix, Arizona • Long Beach, California • Iowa City, Iowa + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 25, 2026, 4:56 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

NCT00251277
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

NCT02836652
View directory record Official record
Conditions
Heart Failure
Interventions
HeartMate II (HMII), Warfarin, acetylsalicylic acid (ASA) therapy
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea

NCT00196391
View directory record Official record
Conditions
Amenorrhea
Interventions
DR-2021a, DR-2021b, DR-2021c, DR-2021d, DR-2021e, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 2Phase 3 Interventional

ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

NCT05070260
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous glenzocimab (ACT017) 1000 mg, Intravenous Placebo
Drug
Lead sponsor
Acticor Biotech
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Bradenton, Florida • St. Petersburg, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 4 Interventional

Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

NCT01873768
View directory record Official record
Conditions
Osteoarthritis
Interventions
Tranexamic Acid (TXA), ε-Aminocaproic Acid (EACA)
Drug
Lead sponsor
Miller Orthopedic Specialists
Other
Eligibility
18 Years to 90 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Council Bluffs, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 25, 2026, 4:56 PM EDT
Withdrawn Phase 3 Interventional

Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding

NCT02066649
View directory record Official record
Conditions
Portal Hypertension Related to Cirrhosis
Interventions
Carvedilol, Variceal band ligation
Drug · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of XP12B in Women With Menorrhagia

NCT00386308
View directory record Official record
Conditions
Menorrhagia, Heavy Menstrual Bleeding
Interventions
Tranexamic acid tablets, Placebo tablets
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Sep 25, 2026, 4:56 PM EDT
Not listed Phase 4 Interventional

Vaginal Estrogen for Asymptomatic Microscopic Hematuria

NCT03033160
View directory record Official record
Conditions
Asymptomatic Microscopic Hematuria
Interventions
Estradiol Ring
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Postoperative Bleeding After Hysterectomy Via Independent Closure of Vaginal Cuff Angles

NCT05174988
View directory record Official record
Conditions
Postoperative Bleeding, Patient Satisfaction, Complications, Operative Time
Interventions
Angle stitch
Procedure
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

NCT02234310
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Up to 17 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
11
States / cities
Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

NCT00708435
View directory record Official record
Conditions
Blood Coagulation Disorders, Acute Major Bleeding
Interventions
Beriplex® P/N (Kcentra), Fresh frozen plasma
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Franciso, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 25, 2026, 4:56 PM EDT